These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23715997)

  • 1. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
    Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
    Brundage MD; Mackillop WJ
    J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in endpoint selection in clinical trials of advanced breast cancer.
    Song SY; Seo H; Kim G; Kim AR; Kim EY
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endpoints in phase II trials for advanced non-small cell lung cancer.
    Mandrekar SJ; Qi Y; Hillman SL; Allen Ziegler KL; Reuter NF; Rowland KM; Kuross SA; Marks RS; Schild SE; Adjei AA
    J Thorac Oncol; 2010 Jan; 5(1):3-9. PubMed ID: 19884856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
    Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
    Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
    Choy H; Gerber DE; Bradley JD; Iyengar P; Monberg M; Treat J; Govindan R; Koustensis A; Barker S; Obasaju C
    Lung Cancer; 2015 Mar; 87(3):232-40. PubMed ID: 25650301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
    BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping.
    Sacher AG; Le LW; Leighl NB
    J Clin Oncol; 2014 May; 32(14):1407-11. PubMed ID: 24590634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.
    Hollen PJ; Gralla RJ; Rittenberg CN
    Support Care Cancer; 2004 Nov; 12(11):767-73. PubMed ID: 15206013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
    Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
    J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
    de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
    J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
    Tanaka S; Sakamori Y; Niimi M; Hazama M; Kim YH; Yanagihara K
    Trials; 2011 May; 12():120. PubMed ID: 21569411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
    Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.